LIANG WANG
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL (NCT07457177) | LIANG WANG | 2026-02-10 |
Track LIANG WANG automatically
Every clearance here is in the API, with alerts when new ones post.